IRI Separation Technologies Inc.

IRI Separation Technologies Inc.

April 30, 2008 09:00 ET

IRI Separation Technologies Inc. Announces Product Availability

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 30, 2008) - IRI Separation Technologies Inc. (TSX VENTURE:IRI) IRI is pleased to announce it has accomplished its targeted milestone of launching its first immune boosting product under the "MUNO®" brand line before the end of April 2008.

The Company is currently negotiating and awaiting purchase orders from several of the major chain drug stores. In the past three weeks we have presented to a growing list of independent pharmacy chains including several independent Co-op type chains in Western Canada and are pleased to announce that we have received product listings for a total of 525 retail outlets.

The Company has received vendor numbers from:

-uniPHARM Wholesale Drug (Richmond B.C.).

-Kohl & Frisch (Toronto), who distribute to the Peoples Drug Mart chain (B.C.) and to Pharmasave Drugs throughout Canada.

The Company is awaiting vendor numbers from:

-Procurity in the Province of Manitoba.

-McKesson Robins of Saskatoon, who handle PharmaChoice in the Province of Saskatchewan.

An extensive advertising campaign, as well as store flyer co-op advertisements, is being undertaken to promote the "MUNO®" brand and the first product, "MUNO® BOOST". Commitments have been made for Flyer advertising of MUNO® products during the months of September and October in the Provinces of Manitoba, Saskatchewan, Alberta and British Columbia. IRI will be attending and participating in drug shows in June and October.

Watch for our next announcement(s) as the products are listed in additional chains and the Media Advertising and Flyer advertising commences.

A website has been created for product information and promotion. The Company will be adding locations at which consumers may purchase the product.

The Website address is:

About IRI Separation Technologies Inc.

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of polyclonal immunoglobulin antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from chicken eggs. The immunoglobulin antibodies are intended for both the general and specific antibody market.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information